×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

Ò»Ð©ÌØÊâÀàÐ͸ßѪѹµÄ»ù±¾¿´·¨

2015-05-15
|
»á¼ûÁ¿£º

5ÔÂ17ÈÕÊÇ¡°ÌìϸßѪѹÈÕ¡± £¬½ñÄêµÄÖ÷ÌâÊÇ¡°ÖªÏþÄúµÄѪѹ¡±¡£É趨ÕâÒ»Ö÷ÌâµÄÄ¿µÄÔÚÓÚÌáÐѸ÷È˾­³£ÕÉÁ¿ÑªÑ¹¡¢Ïàʶ×Ô¼ºµÄѪѹˮƽ £¬ÒÔ±ãʵʱ·¢Ã÷¸ßѪѹ¡£¡°ÖªÏþÄúµÄѪѹ¡±ÓÐÒ»¸öÖ÷ÒªÌõ¼þ £¬¾ÍÊÇÒª¹æ·¶»¯ÕÉÁ¿ÑªÑ¹ £¬Ö»ÓÐÔÆÔÆ²Å»ª»ñȡ׼ȷµÄЧ¹û £¬×öµ½ÖªÏþÄú¡°ÕæÕýµÄ¡±ÑªÑ¹¡£³ý´ËÖ®Íâ £¬ÉÐÓÐÒ»Ð©ÌØÊâÀàÐ͵ĸßѪѹ £¬Ò²»áÓ°Ïìµ½¶ÔѪѹˮƽµÄ׼ȷÆÀ¹À¡£ÏàʶÕâÐ©ÌØÊâÇéÐÎ £¬ÓÐÖúÓÚ¸üºÃµÄ×öºÃ¸ßѪѹµÄɸ²éÊÂÇé¡£

×ðÁú¿­Ê± - ÈËÉú¾ÍÊDz«!


1£®°×´óÒÂÐÔ¸ßѪѹ£ºÒ²³ÆÎªÕïÊÒ¸ßѪѹ¡£ÕâЩ»¼ÕßÔÚÒ½ÔºÕÉÁ¿ÑªÑ¹Ôö¸ß £¬µÖ´ï¸ßѪѹµÄÕï¶Ï±ê×¼ £¬µ«¶¯Ì¬ÑªÑ¹¼à²â»òÔÚ¼ÒÍ¥ÇéÐÎÏÂ×Ô¼ºÕÉÁ¿ÑªÑ¹Ê±ÑªÑ¹Ë®Æ½Õý³£¡£¹ØÓÚÕâÖÖ¸ßѪѹµÄÁÙ´²ÒâÒå £¬ÉÐÎÞÒ»ÖÂÒâ¼û¡£´ó¶¼Ñ§ÕßÒÔΪ £¬°×´óÒÂÐÔ¸ßѪѹ²»ÐèÒªÒ©ÎïÖÎÁÆ¡£µ«´ËÀ໼ÕßδÀ´±¬·¢¸ßѪѹµÄʱ»úÔöÌí £¬Òò´Ë¸üÓ¦ÖØÊÓ¾ÀÕý²»Á¼ÉúÑÄ·½·¨¡£

2£®Òþ²ØÐÔ¸ßѪѹ£º´ËÀ໼ÕßÔÚÒ½Ôº¾ÍÕïʱѪѹˮƽÕý³£ £¬µ«¶¯Ì¬ÑªÑ¹¼à²â»ò¼ÒÍ¥×Ô²âѪѹȴÏÔʾѪѹÉý¸ß¡£Ò¹¼ä¸ßѪѹÊÇÒþ²ØÐÔ¸ßѪѹµÄ³£¼ûÔµ¹ÊÔ­ÓÉ¡£¿µ½¡ÈËÖçҹѪѹˮƽ»áÔÚÒ»¶¨¹æÄ£ÄÚ²¨¶¯ £¬²¢ÇÒÌåÏÖΪÖç¸ßÒ¹µÍµÄÖçÒ¹½ÚÂÉ¡£µ«Ò»Ð©ÈË£¨ÌØÊâÊÇÍíÄêÈË£©µÄÖçÒ¹½ÚÂÉÒì³£ £¬ÌåÏÖΪÖçµÍÒ¹¸ßÐÍ¡£ÔÚ´ËÇéÐÎÏ £¬»¼ÕßÈռ䵽ҽԺ¾ÍÕïʱÕý´¦ÓÚѪѹ½ÏµÍµÄʱ¼ä¶Î £¬Òò´ËÆäÕïÊÒѪѹ¿ÉÄÜÊÇÕý³£µÄ¡£Ò»Ñùƽ³£ÒÔΪ £¬Òþ²ØÐÔ¸ßѪѹ»¼Õß±¬·¢²»Á¼ÐÄѪ¹ÜÊÂÎñµÄΣº¦¸ßÓÚѪѹÕý³£Õß £¬ÒÔÊÇÒ»µ©È·Õï £¬Ó¦¸Ã¶ÔÕâЩ»¼Õß¾ÙÐÐÖÎÁÆ¡£

3£®¼ÙÐÔ¸ßѪѹ£ºËæ×ÅÄêËêÔöÌíÓ붯ÂöÖàÑùÓ²»¯²¡±äµÄÐγÉ £¬Ò»Ð©»¼Õߵ͝Âö½©Ó²¶È»áÔöÌí¡£µ±Ó¦ÓÃÐä´øÑªÑ¹¼ÆÕÉÁ¿Ê± £¬Ëù²âµÃµÄЧ¹û»á±ÈÏÖʵѪѹˮƽÔö¸ß¡£Òò´Ë £¬²¿·ÖѪѹÕý³£Õ߻ᱻÎóÕïΪ¸ßѪѹ¡£ÓÐÑо¿·¢Ã÷ £¬Ô¼4£¥µÄÍíÄêÈËÓÃÐä´øÑªÑ¹¼ÆÕÉÁ¿µÄѪѹÊýÖµ»á±È¶¯ÂöÄÚ²âѹЧ¹ûÔö¸ß30mmHgÒÔÉÏ¡£ÔÚÁÙ´²ÉϼÙÐÔ¸ßѪѹ½ÏÄÑÅжÏ¡£ÓÐѧÕßÒÔΪӦÓÃOslerÊÖ·¨ÓÐÖúÓÚ·¢Ã÷¼ÙÐÔ¸ßѪѹ £¬µ«Ò»Ð©Ñо¿ÏÔʾÕâÒ»ÒªÁìµÄÁÙ´²¼ÛÖµÓÐÏÞ¡£¼ÙÐÔ¸ßѪѹ»áµ¼ÖÂÌ«¹ýµÄ½µÑ¹ÖÎÁÆ £¬ÕâÕýÊÇÆäÖ÷ҪΣº¦ËùÔÚ¡£ÌÈÈô¸ßѪѹ»¼Õß¾­ÓɽµÑ¹Ò©ÎïÖÎÁÆºó·ºÆðÍ·ÔεȵÍѪѹ֢״ £¬Ó¦Ð¡ÐÄÊÇ·ñ±£´æ¼ÙÐÔ¸ßѪѹµÄ¿ÉÄÜ¡£

4£®¼ÙÐÔÕý³£ÑªÑ¹£º¼´Ðä´øÑªÑ¹¼ÆÕÉÁ¿ÑªÑ¹Õý³£ £¬µ«×Åʵ¼ÊѪѹÔö¸ß¡£Æä×î³£¼ûµÄÔµ¹ÊÔ­ÓÉÊÇËø¹Ç϶¯ÂöÏÁÕ­ £¬Òò´Ë»¼ÕßÊ״ξÍÕïÕÉÁ¿ÑªÑ¹Ê±Ò»¶¨ÒªÕÉÁ¿Ë«²àÉϱÛ¡£Õý³£ÇéÐÎÏ £¬Ë«²àÉϱÛѪѹ¿ÉÒÔÓнÏС²î±ð £¬Ò»Ñùƽ³£²»Áè¼Ý10mmHg¡£ÈôÊÇË«²àѪѹÕÉÁ¿ÖµÁè¼Ý20mmHgÔòÓ¦ÐнøÒ»²½¼ì²é£¨Ñª¹Ü³¬ÉùÉõÖÁ¶¯ÂöÔìÓ°£© £¬ÒÔÏàʶÓÐÎÞ¶¯ÂöÏÁÕ­¡£ÔÚÉÙÉÙÊýÇéÐÎÏ £¬ÓÉÓÚË«²àËø¹Ç϶¯Âö¶¼±£´æÏÔ×ÅÏÁÕ­ £¬´Ëʱ˫ÉϱÛѪѹ¾ù»áµÍÓÚÏÖʵѪѹ £¬Îª¸ßѪѹµÄÕï¶Ï´øÀ´ÄÑÌâ¡£ÕâÖÖÇéÐÎÏÂÖ»ÓоÙÐÐÓд´ÑªÑ¹ÕÉÁ¿·½ÄÜÃ÷È·ÕæÊµµÄѪѹˮƽ¡£

ÔÚÁÙ´²ÉÏ £¬ÎªÉ¸²é°×´óÒÂÐÔ¸ßѪѹºÍÒþ²ØÐÔ¸ßѪѹ £¬ÐèÒªÁ¬ÏµÕïÊÒѪѹ¡¢¶¯Ì¬ÑªÑ¹ºÍ¼ÒÍ¥×Ô²âѪѹÈýÖÖ²î±ðµÄÕÉÁ¿·½·¨ £¬×ÛºÏÆÊÎöÆäЧ¹û¡£¹ØÓÚ¼ÙÐÔ¸ßѪѹ»ò¼ÙÐÔÕý³£ÑªÑ¹ £¬È·Õï½ÏΪÄÑÌâ £¬Òɼ°´ËÁ½ÖÖÇéÐÎʱ½¨Òéת¸ßѪѹר¿Æ½øÒ»²½ÕïÖΡ£
Ïà¹ØÐÂÎÅ
¸ßѪѹÓÃÒ©Ô­Ñе±µÀ
2015-12-15
¸ßѪѹÊÇ×î³£¼ûµÄÐÄѪ¹Ü¼²²¡Ö®Ò» £¬¹ú¼Ê¸ßѪѹѧ»á£¨ISH£©½ÒÏþµÄ¸£¸ÔÐûÑÔÖÐÖ¸³ö £¬È«Çò62%µÄ×äÖÐÓɸßѪѹֱ½Óµ¼Ö £¬49%µÄÐ£ËÀÓɸßѪѹËùµ¼Ö £¬¶øÈ«ÇòÓÐ30%µÄÈËËÀÓÚÄÔ×äÖС¢ÐÄÔàÒâÍâµÈÐÄѪ¹Ü¼²²¡¡£
ʯҩ¼¯ÍŸßѪѹעÉäÓÃÈé¼Á»ñÅúÁÙ´²Ø­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ
2023-01-10
1ÔÂ9ÈÕ £¬Ê¯Ò©¼¯ÍÅͨ¸æ £¬¼¯ÍÅÁ¥Êô¹«Ë¾Ê¯Ò©¼¯ÍÅÖÐŵҩҵ£¨Ê¯¼Òׯ£©ÓÐÏÞ¹«Ë¾¿ª·¢µÄ¶¡ËáÂÈάµØÆ½×¢ÉäÓÃÈé¼ÁÒÑ»ñµÃÖлªÈËÃñ¹²ºÍ¹ú¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÅú×¼ £¬¿ÉÒÔÔÚÖйú¿ªÕ¹ÁÙ´²ÊÔÑé¡£¶¡ËáÂÈάµØÆ½ÊÇÒ»ÖÖ¶þÇâßÁà¤Àà¸ÆÍ¨µÀ×èÖͼÁ £¬ÊÊÓÃÓÚÔÚ¿Ú·þ½µÑ¹Ò©²»ÊÊÓûòÎÞ·¨È¡µÃÖª×ãÁÆÐ§µÄÇéÐÎÏÂÖÎÁƸßѪѹ¡£
Ñо¿ÐÂÐͶà°Ðµã¿¹¸ßѪѹҩMT-1207µÄÒ©ÀíÑ§ÌØÕ÷ £¬ÆÀ¼ÛMT-1207µÄÁ¬ÏµÒÖÖÆ»îÐÔͨ¹ý×ðÁú¿­Ê±¾ÙÐÐ
2023-07-05
Hypertension is a serious public health problem worldwide. MT-1207 is a chemical entity that has entered into clinical trial as antihypertensive agent. MT-1207 potently inhibits adrenergic ¦Á1A, ¦Á1B, ¦Á1D, and 5-HT2A receptors with Ki<1 nM in a panel of enzyme activity or radioligand binding assays. The binding inhibition activities of MT-1207 were evaluated by Medicilon.
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿